Skip to main content

Table 2 A collection of preclinical as well as clinical PARPis drugs

From: PARP inhibitors in gastric cancer: beacon of hope

Targeted Drug name Target Study Phase Reference
Pan-PARP Olaparib (Lynparza) PARP1, PARP2 FDA approval (OC) [68]
Niraparib (ZL-2306) PARP1, PARP2 FDA approval (OC) [69]
Rucaparib (PF-01367338) PARP FDA approval (OC) [70]
Talazoparib (BMN-673) PARP1, PARP2 FDA approval (BC) [71]
Veliparib (ABT-888) PARP1, PARP2 phase III (Squamous Non-Small Cell Lung Cancer) NCT02106546
2X-121 TNK 1/2 phase II (Advanced Ovarian Cancer) NCT03878849
CEP-9722 PARP, TNK phase I (Advanced Solid Tumors) NCT04335604
BGB-290 (Pamiparib) PARP1, PARP2 phase II (Advanced or Inoperable Gastric Cancer) NCT03427814
JPI-547 PARP, TNK phase I (Advanced Solid Tumors) NCT04335604
INO-1001 PARP phase I (Melanoma) NCT00272415
A-966492 PARP1, PARP2 Preclinical [72]
PJ-34 HCI PARP Preclinical [73]
UPF1069 PARP1, PARP2 Preclinical [74]
RK-287107 TNK 1/2 Preclinical [75]
IMP4297 PARP1, PARP2 phase I (Advanced Solid Tumors and Small Cell Lung Cancer) NCT04434482
E7449 PARP1, PARP2 Phase I/II (Advanced Solid Tumors/B-cell Malignancies) NCT01618136
NU1025 PARP Preclinical [76]
AZD2461 PARP1 phase I (Refractory Solid Tumors) NCT01247168
NMS-03305293 PARP1 phase I (Selected Advanced/Metastatic Solid Tumors) NCT04182516
Fluzoparib (SHR3162) PARP1 phase II (Relapsed Ovarian Cancer) NCT04517357
3-aminobenzamide PARP1 Preclinical [77]
AG-14361 PARP1 Preclinical [78]
NMS-P118 PARP1 Preclinical [79]
ME0328 PARP3 Preclinical [80]
NA IDX-1197 NA phase II (HRR Mutated Solid Tumors) NCT04174716
E7016 NA phase I (Advanced Solid Tumors) NCT01127178